Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
gptkb:metreleptin
|
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A16AA06
|
| gptkbp:contraindication |
general obesity
hypersensitivity to metreleptin |
| gptkbp:form |
powder for solution for injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Myalept
|
| gptkbp:indication |
generalized lipodystrophy
|
| gptkbp:legalStatus |
Rx-only (US)
|
| gptkbp:manufacturer |
gptkb:Aegerion_Pharmaceuticals
Amryt Pharma |
| gptkbp:mechanismOfAction |
leptin analog
|
| gptkbp:notRecommendedFor |
HIV-related lipodystrophy
partial lipodystrophy |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
gptkb:hypoglycemia
leukemia allergic reaction |
| gptkbp:storage |
refrigerated
|
| gptkbp:usedFor |
metabolic complications of lipodystrophy
|
| gptkbp:bfsParent |
gptkb:metreleptin
gptkb:Aegerion_Pharmaceuticals |
| gptkbp:bfsLayer |
8
|